FDA Grants Breakthrough Status to Natera’s Multi-Cancer Blood Test

FDA granted Breakthrough Device designation on 9 October 2026 to Natera's multi-cancer early detection (MCED) assay, a blood test that screens for multiple cancer types by analyzing cell-free DNA shed into the bloodstream. The designation puts the test on FDA's priority interactive-review track. It does not clear or approve anything, and Natera's announcement is conspicuously quiet on the performance numbers that will ultimately decide whether the assay is good enough to screen people who have no reason to suspect they have cancer.

What Breakthrough status actually buys a sponsor

FDA's Breakthrough Devices Program exists to speed the review of technologies that could offer more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions. In practice, it means more frequent interaction with FDA review staff during development, priority review once a submission is filed, and eligibility for streamlined data-development plans. It does not mean the device works, and it does not mean a clearance or approval is close — Natera's own Signatera test has carried Breakthrough status for several applications since 2019 and is still building out its regulatory record case by case. For an MCED screening test aimed at asymptomatic people, the bar a submission ultimately has to clear is considerably higher than for a test used in patients already known to have cancer, because a false positive sends a healthy person into a cascade of follow-up testing, and a false negative offers false reassurance.

The numbers that are missing

Natera's announcement states that FDA's review considered data across 12 cancer types and evaluated sensitivity, specificity and cancer signal origin performance — language that signals a reasonably developed clinical dataset sits behind the designation. What the release does not say is more consequential for anyone trying to assess the test: no sensitivity or specificity percentages, no CSO accuracy rate, no identification of which 12 cancers were studied, and no description of the population those numbers come from. Multi-cancer screening is a crowded and closely watched category — GRAIL's Galleri test has been through its own advisory-committee scrutiny on this site before, in part because small differences in sensitivity at low cancer prevalence translate into very different numbers of false positives at a population scale. Until Natera publishes or FDA's own review materials disclose the underlying figures, the designation is evidence that FDA found the program promising enough to prioritize, not evidence of how the test will perform in the clinic.

What it means for RA/QA teams

For regulatory teams tracking the MCED category, this designation is a marker to watch rather than an event to react to: it signals Natera intends to pursue FDA marketing authorization for a true screening indication, likely via De Novo or PMA given the novelty of the claim, rather than relying on the laboratory-developed-test pathway Natera and competitors have used for other oncology assays. The regulatory path a sponsor chooses for a screening-intent cancer test, and how FDA treats the clinical-validity bar for signal-origin accuracy specifically, will shape how every other MCED developer designs its own pivotal studies. Teams building submissions in this space should watch for Natera's eventual premarket filing, where the sensitivity, specificity and CSO data withheld from this announcement will have to appear.

Frequently asked questions

What did FDA grant Natera on 9 October 2026?

Breakthrough Device designation for Natera's multi-cancer early detection (MCED) assay, a blood test analyzing cell-free DNA to screen for multiple cancer types. The designation is a priority-review status, not a marketing clearance or approval.

What did FDA's review consider?

Natera says FDA's review covered data from 12 cancer types and assessed sensitivity, specificity and cancer signal origin (CSO) performance — the assay's ability to predict which tissue a detected cancer signal came from.

What hasn't Natera disclosed?

The announcement gives no sensitivity, specificity or CSO accuracy figures, and does not name the 12 cancer types or describe the study population those figures came from.

Is this the same as Natera's Signatera test?

No. Signatera is a tumor-informed ctDNA test for patients already diagnosed with cancer, built around each patient's own tumor mutations; it received its first Breakthrough Device designation in 2019. The MCED assay is a screening test for people without a cancer diagnosis.